CTOs on the Move

Valeant Pharmaceuticals

www.valeant.com

 
Valeant Pharmaceuticals International, Inc. is a diverse and decentralized pharmaceutical company that is committed to focusing on our key stakeholders while delivering consistently high performance. Our values provide the overall direction for our company, and provide us with the tools necessary to rise to any challenge by leveraging our collective hard work and effort along with our unwavering competitive spirit. These values help us set goals based on our organization’s potential and what we hope it will become.
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion
  • www.valeant.com
  • 2150 St. Elzéar Blvd. West
    Laval, QC CAN H7L 4A8
  • Phone: 514.744.6792

Executives

Name Title Contact Details
Michael McDaid
Vice President of Information Technology Profile

Similar Companies

Apertus Pharmaceuticals

API Manufacturing Company

Marker Therapeutics

We are a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker`s cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. Once infused into patients, this population of T cells attacks multiple tumor targets and acts to activate the patient`s immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cells, when compared to current engineered CAR-T and TCR-based approaches, its products (i) are significantly less expensive and easier to manufacture, (ii) appear to be markedly less toxic, and (iii) are associated with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling therapeutic product profile, as compared to current gene-modified CAR-T and TCR-based therapies. Marker is also advancing a number of innovative peptide- and gene-based immuno-therapeutics for the treatment of cancer and metastatic disease, including our Folate Receptor Alpha program (TPIV200) for breast and ovarian cancers and our HER2/neu+ peptide antigen program (TPIV100/110) in Phase II clinical trials. In parallel, we are developing a proprietary DNA expression technology named PolyStart™ to improve the ability of the cellular immune system to recognize and destroy diseased cells.

Soliton

Soliton has developed breakthrough science for tattoo removal using Rapid Acoustic Pulse (RAP) technology, which when combined with existing laser technology can rapidly accelerate tattoo removal.

ABO Pharmaceuticals

ABO Pharmaceuticals is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

I.C.H. Corporation

I.C.H. Corporation is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.